Novavax stock edges higher as FDA clears updated Nuvaxovid for high-risk adults
Published on 08/29/2026 at 19:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novavax Inc. (ISIN US6707721049) stock is holding in the high single digits as of August 28, 2026, with investors weighing fresh second-quarter 2026 results against a newly approved COVID-19 booster for high-risk adults in the United States.
Per recent market data as of August 28, 2026, the Novavax share price closed at $9.26 on the Nasdaq, up 2.32% on the day, leaving the company with a market capitalization that reflects renewed interest in its COVID-19 franchise.
The investor narrative now centers on how an FDA decision to approve an updated protein-based Nuvaxovid shot for older and high-risk Americans could support licensing and royalty income alongside the company’s latest operational metrics.
FDA clears updated Nuvaxovid for high-risk adults
Regulatory momentum has returned to the Novavax vaccine platform after the U.S. Food and Drug Administration approved updated COVID-19 vaccines for the 2026-27 respiratory season, including a protein-based Nuvaxovid shot distributed by Sanofi and originally licensed by Novavax.
According to an infectious disease update published on August 28, 2026, the latest Novavax-Sanofi formulation is the only protein-based, non-mRNA COVID-19 vaccine available in the United States and is authorized for adults aged 65 and older as well as people aged 12 through 64 who have a high-risk health condition.
Additional coverage from a COVID-19 vaccine overview dated August 28, 2026, confirms that the FDA approval covers Nuvaxovid for higher-risk Americans and notes that doses are expected to be available in the coming days, creating a clear path for near-term revenue-sharing between Novavax and its commercial partner.
In parallel, a health news summary dated August 29, 2026, reports that the FDA decision covers four vaccines for the United States market, including the Novavax-Sanofi protein-based shot, underscoring that the updated formulation is part of the core set of COVID-19 boosters for the upcoming season.
For equity holders, the key point is that this regulatory clearance extends the life of Novavax’s COVID-19 asset into the 2026-27 season and positions the company to collect licensing revenue on every dose of Nuvaxovid sold to high-risk adults in the United States.
Q2 2026 results and guidance underpin the story
Beyond the regulatory catalyst, fundamentals from the latest quarter frame how much the Nuvaxovid approval can matter for Novavax over the remainder of 2026.
The Novavax investor relations site highlights that the company reported second-quarter 2026 financial results and operational metrics, marking Q2 2026 as the most recent reporting period for investors to assess.
A detailed earnings recap published around the Q2 2026 release notes that Novavax delivered revenue that exceeded expectations in the quarter and responded by raising its full-year 2026 guidance, signaling that management now anticipates stronger top-line performance than previously communicated.
The same recap describes that the improved outlook for 2026 came against a backdrop of modest share-price gains, including a move where the stock traded at $8.34 and then closed at $8.79 on the day the Q2 2026 news circulated, representing an intraday climb of 5.17% and a full-day gain of 10.84%.
This quantified comparison between earlier trading levels around $8.34 and the $8.79 close on that session underscores how investors reacted positively to revenue strength and guidance improvements, even before the latest FDA decision on the updated Nuvaxovid booster.
Strategically, the combination of a raised full-year 2026 revenue outlook and continued regulatory support for the COVID-19 vaccine franchise gives Novavax more room to invest in its pipeline while still signaling progress toward cash-flow stabilization.
Market data compiled as of August 28, 2026, shows the current Novavax share price at $9.26, implying that the stock is trading modestly above the $8.79 level recorded around the Q2 2026 reaction day, which suggests that investors have continued to assign some value to the improved guidance and the extension of the Nuvaxovid commercial window.
Valuation view and sector backdrop
Fresh analysis of Novavax’s valuation picture points to a company that, despite recent gains, still trades on market multiples that some observers see as stretched rather than clearly cheap.
One recent overview of the stock dated August 29, 2026, notes that the current profile of Novavax screens as overvalued on key ratios compared with certain healthcare peers, even though the share price remains below the double-digit levels seen during earlier pandemic-era rallies.
That perspective means the fundamental narrative now hinges on whether the combination of Q2 2026 revenue strength, raised guidance, and the FDA-backed Nuvaxovid season can translate into sustained earnings improvements that justify the valuation or compress those multiples over time.
The broader COVID-19 vaccine sector also provides context: on the same regulatory decision, mRNA-based manufacturers secured approvals for their updated shots targeting the dominant XFG variant, reinforcing that competition for high-risk adults in the United States remains intense.
For Novavax, the differentiator is that Nuvaxovid offers a protein-based alternative that may appeal to people who prefer non-mRNA platforms, potentially expanding the addressable market segment even if the overall booster market is smaller than in earlier pandemic years.
Investors therefore need to track not only headline approval news but also actual uptake figures for the 2026-27 Nuvaxovid season, as those utilization metrics will feed back into whether the raised 2026 guidance proves conservative or ambitious.
Nuvaxovid as a flagship product
At the product level, Nuvaxovid stands out as Novavax’s flagship commercial vaccine and the asset most directly tied to the current FDA catalyst.
The latest public-health updates place Nuvaxovid, distributed in the United States by Sanofi under license from Novavax, at the center of the non-mRNA COVID-19 booster offering for high-risk adults ahead of the 2026-27 respiratory season.
In practical terms, Nuvaxovid’s protein-based formulation differentiates it from mRNA competitors and can be particularly relevant for some patient groups and physicians who prefer alternative vaccine platforms, giving Novavax a distinct niche even within a crowded booster landscape.
Because Novavax earns revenue through its licensing agreement rather than direct commercial sales in all markets, the scale of Nuvaxovid uptake across regions such as the United States, the European Union, and Japan will influence how much of the raised 2026 guidance ultimately flows from this product.
Novavax stock and current market levels
From a trading perspective, Novavax shares continue to change hands on the Nasdaq, with the latest closing data as of August 28, 2026, showing a price of $9.26 and a daily gain of 2.32%.
That closing level leaves the stock modestly above the reaction price of $8.79 recorded around the Q2 2026 guidance update, suggesting that investors have maintained some of the earlier earnings-related momentum while also factoring in the regulatory boost from the Nuvaxovid approval.
At the same time, recent valuation commentary warning that the stock screens as overvalued on certain multiples highlights that the market is already pricing in a meaningful share of future COVID-19 and pipeline contributions, which could lead to volatility if subsequent quarters fail to match Q2 2026 revenue performance.
For now, the key data points are clear: a Q2 2026 quarter with revenue beating expectations and guidance raised for the full year, a regulatory green light for an updated Nuvaxovid booster for high-risk adults, and a Nasdaq share price of $9.26 as of August 28, 2026, that keeps Novavax in the high-single-digit range.
Go deeper
Investors can find additional operational and financial detail in the second-quarter 2026 results and broader corporate materials available via the Novavax investor relations portal.
Read more
More on Novavax stock and its COVID-19 vaccine strategy appears in the company’s latest quarterly communications and sector-wide analyses of the 2026-27 booster season.
Investor Relations
Company: Novavax Inc.
ISIN: US6707721049
Ticker: NVAX
Exchange: Nasdaq
Price (as of August 28, 2026, 4:00 p.m. ET): $9.26 USD
Sector / Industry: Biotechnology / Vaccines
Index membership: None
